• News Ticker alerts

Biotech Amylin stock is up 18.04% to $14.33 at mid-day Monday (Jan. 30), following Food & Drug Administration approval for U.S. marketing of Bydureon, a once-weekly version of Amylin's diabetes shot.

This was the third try with the FDA. Amylin is working with Alkermes on the drug.

Now, takeover sharks may be circling Amylin, according to Bloomberg News. Those rumors may also be boosting the stock.

  • News Ticker alerts

Comments

Visduh Jan. 31, 2012 @ 8:25 a.m.

It could be wonderful news for long-suffering Amylin shareholders, but not for Amylin employees (unless, of course, they have stock options.)

0

Don Bauder Jan. 31, 2012 @ 3:55 p.m.

Yes, Visduh, those Amylin shareholders have certainly been longsuffering. There were times when the company was right on the edge of extinction. Best, Don Bauder

0

Sign in to comment

Join our
newsletter list

Enter to win $25 at Broken Yolk Cafe

Each newsletter subscription
means another chance to win!

Close